These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12643008)

  • 1. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
    Skeel RT; Huang J; Manola J; Wilding G; Dreicer R; Walker P; Muggia F; Crawford ED; Dutcher JP; Loehrer PJ
    Cancer Invest; 2003; 21(1):41-6. PubMed ID: 12643008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin.
    Lippman SM; Parkinson DR; Itri LM; Weber RS; Schantz SP; Ota DM; Schusterman MA; Krakoff IH; Gutterman JU; Hong WK
    J Natl Cancer Inst; 1992 Feb; 84(4):235-41. PubMed ID: 1734084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.
    Enzinger PC; Ilson DH; Saltz LB; Martin LK; Kelsen DP
    Cancer; 1999 Mar; 85(6):1213-7. PubMed ID: 10189124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
    Lippman SM; Kavanagh JJ; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong WK; Holdener E; Krakoff IH
    J Natl Cancer Inst; 1992 Feb; 84(4):241-5. PubMed ID: 1734085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon.
    Dunst J; Hänsgen G; Lautenschläger C; Füchsel G; Becker A
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):367-73. PubMed ID: 10030263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers.
    Dunst J; Hänsgen G; Krause U; Füchsel G; Köhler U; Becker A
    Strahlenther Onkol; 1998 Nov; 174(11):571-4. PubMed ID: 9830438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
    Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
    J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.
    Slabber CF; Falkson G; Burger W; Schoeman L
    Invest New Drugs; 1996; 14(4):391-4. PubMed ID: 9157075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
    Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
    J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva].
    Römisch M; Meier W; Kimmig R; Hepp H
    Geburtshilfe Frauenheilkd; 1996 Oct; 56(10):520-4. PubMed ID: 9036064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix.
    Hallum AV; Alberts DS; Lippman SM; Inclan L; Shamdas GJ; Childers JM; Surwit EA; Modiano M; Hatch KD
    Gynecol Oncol; 1995 Mar; 56(3):382-6. PubMed ID: 7705672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
    Wadler S; Schwartz EL; Haynes H; Rameau R; Quish A; Mandeli J; Gallagher R; Hallam S; Fields A; Goldberg G; McGill F; Jennings S; Wallach RC; Runowicz CD
    Cancer; 1997 Apr; 79(8):1574-80. PubMed ID: 9118041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.
    Rinaldi DA; Lippman SM; Burris HA; Chou C; Von Hoff DD; Hong WK
    Anticancer Drugs; 1993 Feb; 4(1):33-6. PubMed ID: 8457712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix.
    Lippman SM; Kavanagh JJ; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong WK; Massimini G; Holdener EE; Krakoff IH
    J Natl Cancer Inst; 1993 Mar; 85(6):499-500. PubMed ID: 8445678
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.
    Pazdur R; Bready B; Ajani JA; Abbruzzese JL; Markowitz A; Sugarman S; Jones D; Levin B
    Am J Clin Oncol; 1995 Oct; 18(5):436-8. PubMed ID: 7572763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
    Vaishampayan U; Flaherty L; Du W; Hussain M
    Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha].
    Paredes Espinoza M; Lippman SM; Kavanagh JJ; Delgadillo Madrueño F; Paredes Casillas P; Bañuelos Acosta O; Alvarez Márquez V; Buenrostro Ahued MA; de Alba Ayala I; Arias Castro G
    Rev Invest Clin; 1994; 46(2):105-11. PubMed ID: 8052740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
    Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
    J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of alpha-interferon 2a (alpha-IFN 2a) and 13-cis-retinoic acid (13cRA) in recurrent, pre-treated squamous-cell carcinoma of head and neck (SCCHN).
    Toma S; Airoldi M; Palumbo R; Raffo P; Bumma C
    Int J Cancer; 1997 Feb; 70(4):491-3. PubMed ID: 9033664
    [No Abstract]   [Full Text] [Related]  

  • 20. Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma.
    Jaremtchuk AV; Aman EF; Ponce W; Zarbá JJ; Ferro AM; Alvarez R; Vigo SA
    Am J Clin Oncol; 2002 Apr; 25(2):123-5. PubMed ID: 11943887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.